Merck is trading at $153.63 (+3.11%) after its jointly developed cancer vaccine with Moderna met both Phase 3 melanoma endpoints.
- INTerpath-001 showed statistically significant, clinically meaningful improvements in recurrence-free and distant metastasis-free survival versus Keytruda alone.
- The results are extending investor interest; the companies plan regulatory discussions and future data presentation, supporting optimism about Keytruda’s longer-term growth prospects.